Gtnx, Inc. v. Inttra, Inc.

789 F.3d 1309, 115 U.S.P.Q. 2d (BNA) 1178, 2015 U.S. App. LEXIS 10083, 2015 WL 3692319
CourtCourt of Appeals for the Federal Circuit
DecidedJune 16, 2015
Docket2015-1349, 2015-1350, 2015-1352, 2015-1353
StatusPublished
Cited by25 cases

This text of 789 F.3d 1309 (Gtnx, Inc. v. Inttra, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gtnx, Inc. v. Inttra, Inc., 789 F.3d 1309, 115 U.S.P.Q. 2d (BNA) 1178, 2015 U.S. App. LEXIS 10083, 2015 WL 3692319 (Fed. Cir. 2015).

Opinion

ON MOTION

TARANTO, Circuit Judge.

At the request of GTNX, Inc., the Patent Trial and Appeal Board instituted “covered business method patent” review proceedings for four patents owned by INTTRA, Inc. A few months later, the Board reconsidered its institution decisions, determined that institution of proceedings in these matters violated a statutory proscription, vacated the institution decisions, and terminated the proceedings. GTNX, Inc. v. INTTRA, Inc., CBM2014-00073 et al., 2014 WL 7723800 (PTAB Dec. 10, 2014). GTNX appeals, and INTTRA moves to dismiss the appeal. We grant the motion. In addition, treating the appeal in the alternative as a mandamus petition, we deny mandamus relief.

BACKGROUND

A

In the' Leahy-Smith America Invents Act, Pub.L. No. 112-29, § 18, 125 Stat. 284, 329-31 (2011), Congress required the Patent and Trademark Office to establish a “transitional post-grant review proceeding for review of the validity of covered business method patents.” § 18(a)(1). Section 18(a)(1) states a general rule, subject to exceptions not material here, that the PTO must “employ,” for such review, the “standards and procedures of[ ] a post-grant review under chapter 32 of title 35,” i.e., 35 U.S.C. §§ 321-329.

Section 324 authorizes the Director of the PTO to institute post-grant review, but by regulation, the Director has delegated to the Board the responsibility to make the institution determination. 37 C.F.R. §§ 42.4, 42.208. Of relevance to this case, 35 U.S.C. § 325(a)(1) declares that “review may not be instituted ... if, before the date on which the petition for such a review is filed, the petitioner or real party in interest filed a civil action challenging the validity of a claim of the patent.” And § 324(e) declares that “[t]he determination by the Director whether to institute a post-grant review under this section shall be final and nonappealable.”

Once review has been instituted, the Board conducts the post-grant review. § 326(c). “If a post-grant review is instituted and not dismissed under this chapter,” the Board “shall issue a final written decision with respect to the patentability of any patent claim challenged by the petitioner and any new claim added under section 326(d).” § 328(a). Section 329 authorizes a party dissatisfied with the Board’s final written decision with respect to patentability to appeal to this court under 35 U.S.C. § 141(c), and 28 U.S.C. *1311 § 1295(a)(4)(A) grants this court jurisdiction over such an appeal.

B

INTTRA owns four patents relating to online methods for coordinating containerized shipping. In 2011, GT Nexus, Inc., GTNX’s parent company, filed suit in the United States District Court for the Northern District of California, seeking a declaratory judgment that INTTRA’s shipping methods patents were invalid. Several years later, in early 2014, while the court case was pending, GTNX petitioned the PTO to review the patents as covered-business-method patents. See GTNX, 2014 WL 7723800, at *1-2.

On August 12, 2014, the Board instituted review proceedings (four separate proceedings which the Board then treated together). Id. at *1. In October 2014, however, the Board granted INTTRA leave to file a motion to dismiss the proceedings on the ground that § 325(a)(1) barred the reviews because of GTNX’s previously filed civil action. Id. After INTTRA filed the authorized motion, GTNX opposed, arguing that INTTRA had waived the § 325(a)(1) objection by not presenting it earlier, either before institution or within the 14 days allowed by the rule giving a right to seek reconsideration, 37 C.F.R. § 42.71(d). Id. at *2.

On December 10, 2014, the Board granted INTTRA’s motion. It “vacated” the August 2014 institution decisions and “terminated” the proceedings, id. at *1, *3, without addressing any issues of patenta-bility. The Board noted that there was no dispute that GTNX’s declaratory-judgment action fell within the terms of § 325(a)(1). Id. at *2. And it concluded that § 325(a)(1) is a statutory limit on Board “jurisdiction” that it could not and would not decline to enforce just because INTTRA had not invoked it earlier. Id.

Characterizing the ruling as a final written decision under § 328, GTNX appeals under § 329, which provides for appeals under § 141. INTTRA moves to dismiss.

Discussion

We agree with INTTRA that GTNX’s appeal falls outside 35 U.S.C. §§ 141 and 329 and hence outside this court’s jurisdiction under 28 U.S.C. § 1295(a)(4)(A).

By its terms, § 329 authorizes appeal, under § 141(c), only from a “final written decision of the [Board] under section 328(a).” Similarly, § 141(c), as relevant here, authorizes appeal only from a “final written decision of the [Board] under section ... 328(a).” In turn, § 328(a) refers only to “a final written decision with respect to the patentability of any patent claim challenged by the petitioner and any new claim added under section 326(d).” § 328(a) (emphasis added). Here, the Board made no decision “with respect to the patentability” of any claim. The Board decision at issue, therefore, is outside § 328(a) and, hence, outside §§ 141(c) and 329.

In St. Jude Medical, Cardiology Division, Inc. v. Volcano Corp., we dismissed an appeal from a non-institution decision under chapter 31 of Title 35, which establishes a regime for “inter partes review” of issued patents that is materially the same as chapter 32 in the particular jurisdictional respects relevant here. 749 F.3d 1373 (Fed.Cir.2014). We explained the structural contrast between a “determination ... whether to institute” a proceeding, which is “final and nonappealable,” 35 U.S.C. § 314(d), and the “final written decision” determining patentability, § 318(a), and we held that the appeal authorization there — § 319, incorporating § 141(c) — was limited to the final written decision on patentability. Id. at 1375-76. We thus *1312 relied on chapter 3Í’s textually clear and common-sense distinction between a final Board decision that reaches the patentability merits and an earlier decision whether to institute. We concluded that 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nursecon, LLC
TTAB, 2024
Mirror Worlds Technologies, LLC v. Meta Platforms, Inc.
122 F.4th 860 (Federal Circuit, 2024)
Hekmati v. United States
51 F.4th 1066 (Federal Circuit, 2022)
In Re VIVINT, INC.
Federal Circuit, 2021
Cywee Group Ltd. v. Google LLC
Federal Circuit, 2021
Mylan Laboratories Ltd. v. Janssen Pharmaceutica, N.V.
989 F.3d 1375 (Federal Circuit, 2021)
Erwin Hymer Grp. N. Am., Inc. v. United States
930 F.3d 1370 (Federal Circuit, 2019)
In Re: Power Integrations, Inc.
899 F.3d 1316 (Federal Circuit, 2018)
Return Mail, Inc. v. United States Postal Service
868 F.3d 1350 (Federal Circuit, 2017)
Credit Acceptance Corp. v. Westlake Services
859 F.3d 1044 (Federal Circuit, 2017)
Medtronic, Inc. v. Lee
151 F. Supp. 3d 665 (E.D. Virginia, 2016)
Achates Reference Publishing, Inc. v. Apple Inc.
803 F.3d 652 (Federal Circuit, 2015)
Versata Development Group, Inc. v. Lee
793 F.3d 1352 (Federal Circuit, 2015)
Versata Development Group, Inc. v. SAP America, Inc.
793 F.3d 1306 (Federal Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
789 F.3d 1309, 115 U.S.P.Q. 2d (BNA) 1178, 2015 U.S. App. LEXIS 10083, 2015 WL 3692319, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gtnx-inc-v-inttra-inc-cafc-2015.